# Erasca to Present at the Bank of America Securities Health Care Conference
Canonical URL: https://biopharmsignal.com/news/ERAS/erasca-to-present-at-the-bank-of-america-securities-health-care-conference
Ticker: ERAS
Company: Erasca
Source: Erasca
Published: 2026-05-06 12:00 EST
Original Source URL: https://investors.erasca.com
## Summary

SAN DIEGO, May 06, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced its participation in the Bank of

## Article Body
SAN DIEGO, May 06, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced its participation in the Bank of
## Recent Company News
- 2026-05-27 12:00 EST — [Erasca to Present at the Jefferies Global Healthcare Conference](https://biopharmsignal.com/news/ERAS/erasca-to-present-at-the-jefferies-global-healthcare-conference) — Source: Erasca
- 2026-05-11 20:01 EST — [Erasca Reports First Quarter 2026 Business Updates and Financial Results](https://biopharmsignal.com/news/ERAS/erasca-reports-first-quarter-2026-business-updates-and-financial-results) — Source: Erasca
- 2026-05-11 11:00 EST — [Erasca Announces Clinical Trial Collaboration and Supply Agreement with Merck to Evaluate ERAS-0015 in Combination with KEYTRUDA® (Pembrolizumab)](https://biopharmsignal.com/news/ERAS/erasca-announces-clinical-trial-collaboration-and-supply-agreement-with-merck-to-evaluate-eras-0015-in-combination-with-keytrudar-pembrolizumab) — Source: Erasca
- 2026-05-06 12:00 EST — [Erasca to Present at the Bank of America Securities Health Care Conference](https://biopharmsignal.com/news/ERAS/erasca-to-present-at-the-bank-of-america-securities-health-care-conference) — Source: Erasca
- 2026-04-27 20:01 EST — [Erasca Announces Positive Preliminary Phase 1 Dose Escalation Data for Potentially Best-in-Class Pan-RAS Molecular Glue ERAS-0015 in KRAS-Mutant Solid Tumors](https://biopharmsignal.com/news/ERAS/erasca-announces-positive-preliminary-phase-1-dose-escalation-data-for-potentially-best-in-class-pan-ras-molecular-glue-eras-0015-in-kras-mutant-solid-tumors) — Source: Erasca
## Related News
- 2026-07-21 20:15 EST — BFRG — [BullFrog AI to Participate in Water Tower Research Fireside Chat on Thursday, July 23, 2026](https://biopharmsignal.com/news/BFRG/bullfrog-ai-to-participate-in-water-tower-research-fireside-chat-on-thursday-jul-78357ce8)
- 2026-07-21 20:05 EST — CLPT — [ClearPoint Neuro to Announce Second Quarter 2026 Results August 3, 2026](https://biopharmsignal.com/news/CLPT/clearpoint-neuro-to-announce-second-quarter-2026-results-august-3-2026-6e4f3c05)
- 2026-07-21 20:05 EST — TCMD — [Tactile Medical to Release Second Quarter of Fiscal Year 2026 Financial Results on August 10, 2026](https://biopharmsignal.com/news/TCMD/tactile-medical-to-release-second-quarter-of-fiscal-year-2026-financial-results--798d4004)
- 2026-07-21 20:05 EST — PIII — [P3 Health Partners Schedules Second Quarter 2026 Earnings Release and Conference Call](https://biopharmsignal.com/news/PIII/p3-health-partners-schedules-second-quarter-2026-earnings-release-and-conference-6c9bd8a7)
- 2026-07-21 12:05 EST — VRCA — [Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel](https://biopharmsignal.com/news/VRCA/verrica-pharmaceuticals-and-medomie-pharma-enter-into-exclusive-distribution-mar-abf61522)